GeneNews (TSX:GEN) has signed an agreement with a large, multi-specialty physician group in the American Midwest for use of its cancer diagnostic tests.Read More
The validation program for 3D Signatures’ (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) Hodgkin's lymphoma test (Telo-HL) is under way. Telo-HL is powered by the company's TeloView software platform.Read More
GeneNews (TSX:GEN) has entered into a partnership agreement with closely-held NueHealth, which delivers value-based healthcare solutions and connects patients directly to physicians through integrated provider networks.
Patients who access healthcare through NueHealth's provider networks will now be able to take advantage of three different screening tests: ColonSentry, earlyCDT-Lung and Prostate Health Index, which provide early risk stratification of colorectal, lung and prostate cancers.Read More